Consequently, the combination of an ATR inhibitor with agents such as cisplatin could be an attractive therapeutic option for lung cancer and for other indications that have a reliance on ATR for survival following treatment with DNA damaging therapy. This evidence concerns the gene ATR and lung cancer.